Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 164Breast Neoplasms 111Colorectal Neoplasms 77Neoplasms 65Lung Neoplasms 61Pancreatic Neoplasms 56Stomach Neoplasms 52Neoplasm Metastasis 51Ovarian Neoplasms 45Rectal Neoplasms 43Esophageal Squamous Cell Carcinoma 38Esophageal Neoplasms 38Head and Neck Neoplasms 34Squamous Cell Carcinoma of Head and Neck 32Leukemia, Myeloid, Acute 32Recurrence 26Triple Negative Breast Neoplasms 25Small Cell Lung Carcinoma 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Glioblastoma 23Colonic Neoplasms 23Uterine Cervical Neoplasms 22Nasopharyngeal Carcinoma 22Lymphoma 21Lymphoma, Non-Hodgkin 20Fallopian Tube Neoplasms 20Prostatic Neoplasms 17Melanoma 17Sarcoma 16Leukemia 16

Interventions

Immunotherapy 2anlotinib 1Radiotherapy 1Drug Therapy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Non-small Cell Lung Cancer × Drug Therapy × Clear all
NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡